Hatfield SM[au] - Search Results

Year	Number of Results
1979	1
1980	1
1981	1
1982	3
1985	2
1986	2
1987	1
1988	2
1991	2
1992	2
2014	1
2015	2
2016	1
2017	1
2020	4
2021	1
2022	1

1

Immunological mechanisms of the antitumor effects of supplemental oxygenation.

Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, Thayer M, Rodig S, Kutok JL, Jackson EK, Karger B, Podack ER, Ohta A, Sitkovsky MV. Hatfield SM, et al. Sci Transl Med. 2015 Mar 4;7(277):277ra30. doi: 10.1126/scitranslmed.aaa1260. Sci Transl Med. 2015. PMID: 25739764 Free PMC article.

2

Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy.

Hatfield SM, Sitkovsky MV. Hatfield SM, et al. J Clin Invest. 2020 Nov 2;130(11):5629-5637. doi: 10.1172/JCI137554. J Clin Invest. 2020. PMID: 32870821 Free PMC article. Review.

3

Editorial overview: Cancer 2020 current mechanistic insights into the hypoxia-adenosine-A2A adenosinergic immunosuppressive axis in cancer immunotherapies.

Beavis PA, Hatfield SM. Beavis PA, et al. Among authors: hatfield sm. Curr Opin Pharmacol. 2020 Aug;53:iii-v. doi: 10.1016/j.coph.2020.10.012. Curr Opin Pharmacol. 2020. PMID: 33183677 No abstract available.

4

Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.

Halpin-Veszeleiova K, Hatfield SM. Halpin-Veszeleiova K, et al. Among authors: hatfield sm. Curr Opin Pharmacol. 2020 Aug;53:84-90. doi: 10.1016/j.coph.2020.07.005. Epub 2020 Aug 22. Curr Opin Pharmacol. 2020. PMID: 32841869 Review.

5

Targeting Hypoxia-A2A Adenosinergic Immunosuppression of Antitumor T Cells During Cancer Immunotherapy.

Steingold JM, Hatfield SM. Steingold JM, et al. Among authors: hatfield sm. Front Immunol. 2020 Sep 29;11:570041. doi: 10.3389/fimmu.2020.570041. eCollection 2020. Front Immunol. 2020. PMID: 33117358 Free PMC article. Review.

6

A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.

Hatfield SM, Sitkovsky M. Hatfield SM, et al. Curr Opin Pharmacol. 2016 Aug;29:90-6. doi: 10.1016/j.coph.2016.06.009. Epub 2016 Jul 17. Curr Opin Pharmacol. 2016. PMID: 27429212 Free PMC article. Review.

7

Therapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients.

Halpin-Veszeleiova K, Hatfield SM. Halpin-Veszeleiova K, et al. Among authors: hatfield sm. Physiology (Bethesda). 2022 Jan 1;37(1):46-52. doi: 10.1152/physiol.00010.2021. Epub 2021 Sep 6. Physiology (Bethesda). 2022. PMID: 34486395 Free PMC article.

8

Mupirocin: a topical antibiotic with a unique structure and mechanism of action.

Parenti MA, Hatfield SM, Leyden JJ. Parenti MA, et al. Among authors: hatfield sm. Clin Pharm. 1987 Oct;6(10):761-70. Clin Pharm. 1987. PMID: 3146455 Review.

9

Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators.

Hatfield SM, Sitkovsky M. Hatfield SM, et al. Oncoimmunology. 2015 Jun 1;4(12):e1052934. doi: 10.1080/2162402X.2015.1052934. eCollection 2015 Dec. Oncoimmunology. 2015. PMID: 26587328 Free PMC article.

10

Alterations in lymphocyte subpopulations in copper-deficient mice.

Lukasewycz OA, Prohaska JR, Meyer SG, Schmidtke JR, Hatfield SM, Marder P. Lukasewycz OA, et al. Among authors: hatfield sm. Infect Immun. 1985 Jun;48(3):644-7. doi: 10.1128/iai.48.3.644-647.1985. Infect Immun. 1985. PMID: 3997239 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results